Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Treatment

Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure

Acute Respiratory Insufficiency

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Aug 2012
Primary outcome: Primary: Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most) — 3.2; 3.3 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Total face mask (interface for NPPV) (Device); Comfort full or RT040 oronasal mask (interface for NPPV) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Tufts Medical Center
Primary completion
Jun 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most)
3.2; 3.3
PRIMARY
Time Required for Mask Placement
5; 3.5
SECONDARY
Early NIV Discontinuation Rate
12; 16
SECONDARY
Deterioration Vital Signs
7; 3
SECONDARY
Deterioration in Gas Exchange
3; 3
SECONDARY
Total Length of Time Requiring NIV
15.7; 6.05
SECONDARY
Length of Hospital Stay
19.2; 10.9
SECONDARY
In-hospital Mortality Rate
6; 3

Summary

The purpose of this study is to compare the Total Face Mask™ (Respironics, Inc., Pittsburgh, PA) (covering whole face) and the standard oronasal facemask (covering nose and mouth) for the emergency treatment of patients with acute respiratory failure with the machine blowing air into the mask placed on the face (noninvasive positive pressure ventilation) (NPPV).

Eligibility Criteria

Inclusion Criteria

  • Age>18
  • Either A or B

A. Clinical Criteria: Moderate to severe respiratory distress as evidenced by tachypnea, use of accessory muscles for breathing, or abdominal paradox.

B. Blood Gas and Physiologic Criteria: Gas exchange abnormalities including PaCO2>45 with a pH<7.35, or a PaO2/FiO2 ratio<200.

Exclusion Criteria

  • The need for immediate intubation
  • Medical instability such as hypotensive shock, uncontrolled cardiac ischemia or arrythmias, unstable myocardial infarction, uncontrolled upper gastrointestinal bleeding
  • Agitation or uncooperativeness, unresponsive to small doses of sedatives
  • Excretions or inability to protect the airway
  • Inability to fit the mask
  • Facial trauma
  • Upper airway obstruction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00686257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search